Robert W. Baird Lowers Charles River Laboratories International (NYSE:CRL) Price Target to $239.00

Charles River Laboratories International (NYSE:CRL) had its price target reduced by stock analysts at Robert W. Baird from $271.00 to $239.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has an “outperform” rating on the medical research company’s stock. Robert W. Baird’s target price would indicate a potential upside of 13.33% from the stock’s current price.

Several other equities analysts have also recently weighed in on CRL. The Goldman Sachs Group started coverage on Charles River Laboratories International in a report on Thursday, June 6th. They set a “buy” rating and a $290.00 price objective on the stock. Barclays started coverage on shares of Charles River Laboratories International in a report on Friday, June 28th. They issued an “equal weight” rating and a $230.00 price target for the company. StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Friday, June 14th. Argus reaffirmed a “hold” rating on shares of Charles River Laboratories International in a research report on Friday, June 28th. Finally, Mizuho started coverage on Charles River Laboratories International in a report on Friday, June 7th. They set a “neutral” rating and a $235.00 target price for the company. Eight analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $252.29.

Charles River Laboratories International Trading Up 4.0 %

CRL opened at $210.88 on Wednesday. The firm’s fifty day moving average is $214.81 and its two-hundred day moving average is $230.87. The firm has a market cap of $10.86 billion, a PE ratio of 24.81, a price-to-earnings-growth ratio of 1.92 and a beta of 1.38. Charles River Laboratories International has a twelve month low of $161.65 and a twelve month high of $275.00. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.37 and a current ratio of 1.75.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Thursday, May 9th. The medical research company reported $2.27 EPS for the quarter, beating analysts’ consensus estimates of $2.05 by $0.22. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $997.24 million. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. Equities research analysts anticipate that Charles River Laboratories International will post 11 EPS for the current year.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 1,304 shares of the company’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $226.97, for a total transaction of $295,968.88. Following the sale, the executive vice president now owns 23,276 shares in the company, valued at approximately $5,282,953.72. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 1.30% of the company’s stock.

Institutional Trading of Charles River Laboratories International

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Deutsche Bank AG raised its holdings in shares of Charles River Laboratories International by 6.9% in the 3rd quarter. Deutsche Bank AG now owns 123,119 shares of the medical research company’s stock valued at $24,129,000 after purchasing an additional 7,944 shares during the period. Neo Ivy Capital Management acquired a new stake in shares of Charles River Laboratories International in the third quarter valued at approximately $216,000. VisionPoint Advisory Group LLC boosted its stake in shares of Charles River Laboratories International by 105.7% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock worth $28,000 after acquiring an additional 74 shares during the period. Vanguard Group Inc. lifted its holdings in Charles River Laboratories International by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 5,953,860 shares of the medical research company’s stock valued at $1,166,837,000 after purchasing an additional 29,482 shares during the last quarter. Finally, Massmutual Trust Co. FSB ADV increased its holdings in shares of Charles River Laboratories International by 21.5% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 328 shares of the medical research company’s stock valued at $78,000 after purchasing an additional 58 shares during the last quarter. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).